PFN1 encodes profilin 1, a small 15-kDa actin-binding protein that regulates actin polymerization and depolymerization. Profilin 1 is essential for cytoskeletal dynamics, cellular motility, synaptic function, and numerous cellular processes. As a fundamental regulator of the actin cytoskeleton, PFN1 plays critical roles in neuronal morphogenesis, axonal guidance, dendritic spine formation, and synaptic plasticity.
The discovery of PFN1 mutations in familial amyotrophic lateral sclerosis (ALS) in 2012 established cytoskeletal dysfunction as a key pathway in motor neuron disease[1]. Since then, research has revealed that PFN1 mutations cause ALS through multiple pathogenic mechanisms including disrupted actin dynamics, impaired autophagy, mitochondrial dysfunction, and altered RNA granule trafficking. Beyond ALS, PFN1 has been implicated in frontotemporal dementia (FTD), Parkinson's disease, and Charcot-Marie-Tooth disease, highlighting its importance in broader neurodegenerative processes[2].
| Profilin 1 (PFN1) | |
|---|---|
| Gene Symbol | PFN1 |
| Protein Name | Profilin-1 |
| Chromosome | 17p13.3 |
| NCBI Gene ID | [5216](https://www.ncbi.nlm.nih.gov/gene/5216) |
| OMIM | 176610 |
| Ensembl ID | ENSG00000108518 |
| UniProt ID | [P07737](https://www.uniprot.org/uniprot/P07737) |
| Protein Family | Profilin family |
| Subcellular Location | Cytoplasm, membrane-associated |
| Associated Diseases | ALS, FTD, PD, Charcot-Marie-Tooth |
The PFN1 gene is located on chromosome 17p13.3 and spans approximately 4.5 kb of genomic DNA. The gene consists of 4 exons that encode a protein of 140 amino acids with a molecular weight of approximately 15 kDa. The gene promoter contains multiple regulatory elements including GC-rich regions and transcription factor binding sites that enable tissue-specific expression[1:1].
Profilin 1 adopts a compact globular structure composed of:
The protein contains two major binding interfaces:
Profilin 1 is a fundamental regulator of actin dynamics through multiple mechanisms[3]:
Beyond actin regulation, profilin 1 participates in:
Profilin 1 interacts with numerous cellular proteins:
| Partner | Function |
|---|---|
| G-actin | Actin dynamics |
| Polyproline proteins | Diverse signaling |
| PLD (phospholipase D) | Membrane trafficking |
| Rho GTPases | Cytoskeletal regulation |
| VASP | Cytoskeletal assembly |
| Ena/VASP proteins | Filopodia formation |
| Formins | Actin polymerization |
Profilin 1 is ubiquitously expressed with highest levels in:
Within the brain, PFN1 shows distinctive patterns:
PFN1 was first linked to familial ALS in 2012 when exome sequencing identified pathogenic mutations in affected families[1:2]. Since then, multiple PFN1 mutations have been identified:
| Mutation | Location | Pathogenic Evidence |
|---|---|---|
| C71G | Exon 2 | Segregates with disease |
| M114T | Exon 3 | In vitro functional assays |
| G118V | Exon 3 | Segregates with disease |
| E117D | Exon 3 | Variable penetrance |
| A92T | Exon 2 | Reported in families |
PFN1 mutations account for approximately 1-2% of familial ALS cases and demonstrate autosomal dominant inheritance with variable expressivity[4].
PFN1 mutations cause ALS through multiple interconnected mechanisms[2:1][5]:
Disrupted actin dynamics:
Impaired autophagy:
Mitochondrial dysfunction:
RNA granule trafficking:
Aggregation propensity:
| Model | Modification | Phenotype |
|---|---|---|
| PFN1 knockout | Deletion | Embryonic lethal |
| PFN1 knockin (C71G) | Point mutation | ALS-like phenotype |
| PFN1 knockin (G118V) | Point mutation | Motor neuron degeneration |
| Motor neuron-specific KO | Conditional | Progressive weakness |
PFN1 mutations have also been identified in FTD cases, establishing a link between cytoskeletal dysfunction and FTD spectrum disorders[7]:
In Parkinson's disease, profilin 1 plays roles in:
| Strategy | Approach | Development Status |
|---|---|---|
| Gene therapy | AAV-PFN1 delivery | Preclinical |
| Actin modulators | Small molecules targeting actin dynamics | Research |
| Autophagy enhancers | mTOR inhibitors, rapamycin | Research |
| Mitochondrial protectants | CoQ10, idebenone | Research |
| Protein aggregation inhibitors | Compound screening | Preclinical |
Recent efforts have focused on developing actin-targeting compounds for ALS[9][10]:
Recent genetic screens have identified PFN1 synthetic lethal partners[11]:
PFN1 connects to multiple NeuroWiki pages:
Wu CH, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012. ↩︎ ↩︎ ↩︎
Aladesuyi A, et al. Profilin-1 and the pathogenesis of ALS. Nature Reviews Neurology. 2023. ↩︎ ↩︎
Pun S, et al. Profilin1 in synaptic development and function. Current Opinion in Neurobiology. 2019. ↩︎
Smith BN, et al. Exome-wide rare variant analysis in familial ALS. Neurology. 2013. ↩︎
Fil D, et al. Pathological features of profilin-1-related ALS. Acta Neuropathol Commun. 2017. ↩︎
March ZM, et al. ALS-associated PFN1 mutations and aggregate formation. Human Molecular Genetics. 2016. ↩︎
Boeddinghaus IM, et al. Profilin1 and FTD spectrum disorders. Brain. 2020. ↩︎
Oles C, et al. PFN1 in alpha-synuclein aggregation. Acta Neuropathologica. 2019. ↩︎
Deng J, et al. Actin-binding compounds for ALS therapy. Journal of Medicinal Chemistry. 2022. ↩︎
Schwab K, et al. Targeting actin dynamics for ALS therapy. Drug Discovery Today. 2018. ↩︎
Liu Y, et al. Profilin1 CRISPR screening in ALS. Nature Neuroscience. 2023. ↩︎